Overview

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

Status:
Completed
Trial end date:
2017-06-21
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of FG-3019 in subjects with Idiopathic Pulmonary Fibrosis (IPF) and the efficacy of FG-3019 for attenuating fibrosis in these subjects.
Phase:
Phase 2
Details
Lead Sponsor:
FibroGen
Treatments:
Antibodies, Monoclonal